Clinical trial results:
A randomized multicenter phase II trial of a sequential chemotherapy of nab-paclitaxel + gemcitabine followed by FOLFIRI.3 versus nab-paclitaxel + gemcitabine in first line of pancreatic adenocarcinoma

Summary

EudraCT number	2014-004449-28
Trial protocol	FR
Global end of trial date	31 March 2021

Results information

Result version number	v1 (current)
This version publication date	03 August 2025
First version publication date	03 August 2025

Trial information

Trial identification

Sponsor protocol code	PRODIGE 37

Additional study identifiers

ISRCTN number	-
ClinicalTrials.gov id (NCT number)	NCT02827201
WHO universal trial number (UTN)	-

Notes:

Sponsors

Sponsor organisation name	Fédération Francophone de Cancérologie Digestive (FFCD)
Sponsor organisation address	7 Boulevard Jeanne d'Arc, BP 87900, Dijon, France, 21079
Public contact	Marie Moreau, Fédération Francophone de Cancérologie Digestive (FFCD), +33 0755676632, marie.moreau@u-bourgogne.fr
Scientific contact	Marie Moreau, Fédération Francophone de Cancérologie Digestive (FFCD), +33 0755676632, marie.moreau@u-bourgogne.fr

Notes:

Paediatric regulatory details

Is trial part of an agreed paediatric investigation plan (PIP)	No
Does article 45 of REGULATION (EC) No 1901/2006 apply to this trial?	No
Does article 46 of REGULATION (EC) No 1901/2006 apply to this trial?	No

Notes:

Results analysis stage

Analysis stage	Final
Date of interim/final analysis	20 August 2019
Is this the analysis of the primary completion data?	Yes
Primary completion date	05 November 2018
Global end of trial reached?	Yes
Global end of trial date	31 March 2021
Was the trial ended prematurely?	No

Notes:

General information about the trial

Main objective of the trial:

Patient rate in live and without radiological and/or clinical progression at 6 months after randomization

Protection of trial subjects:

The study was conducted in accordance with the ethical principles outlined in the Declaration of Helsinki, ICH requirements and Good Clinical Practice guidelines; it received authorization from the French national medicines agency (ASNM), and independent ethics committee. The study was registered in clinical trials.gov (NCT02827201). All patients provided their written informed consent before the initiation of the study.

Background therapy: -

Evidence for comparator: -

Actual start date of recruitment	15 April 2015
Long term follow-up planned	No
Independent data monitoring committee (IDMC) involvement?	No

Notes:

Population of trial subjects

Subjects enrolled per country

Country: Number of subjects enrolled	France: 127
Worldwide total number of subjects	127
EEA total number of subjects	127

Notes:

Subjects enrolled per age group

In utero	0
Preterm newborn - gestational age < 37 wk	0
Newborns (0-27 days)	0
Infants and toddlers (28 days-23 months)	0
Children (2-11 years)	0
Adolescents (12-17 years)	0
Adults (18-64 years)	52
From 65 to 84 years	75
85 years and over	0

Subject disposition

Recruitment

Recruitment details:

Between November 2015 and November 2016, 127 patients were enrolled in the trial by 36 french centres.

Pre-assignment

Screening details:

Baseline computerised tomography (CT) scan, or magnetic resonance imaging (MRI), was performed within 3 weeks before the start of treatment. In the week preceding the start of treatment, patients underwent medical history evaluation, physical examination, assessment of health-related quality of life (QoL), electrocardiogram, biological assessment.

Period 1

Period 1 title	Baseline period (overall period)
Is this the baseline period?	Yes
Allocation method	Randomised - controlled
Blinding used	Not blinded

Arms

Are arms mutually exclusive?	Yes
Arm title	arm A : GN + FOLFIRI.3

Arm description:

gemcitabine + nab-paclitaxel + FOLFIRI.3 =FIRGEMAX arm

Arm type	Experimental
Investigational medicinal product name	Gemcitabine
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Powder for concentrate and solution for solution for infusion
Routes of administration	Intravenous use

Dosage and administration details:

1000 mg/m2 I.V. for 30 min for a total of six doses on days 1, 8, 15, 29, 36 and 43

Investigational medicinal product name	Nab-paclitaxel
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Solution for injection
Routes of administration	Intravenous use

Dosage and administration details:

2 months of nab-paclitaxel (125 mg/m2) I.V. for 30 min immediately followed by gemcitabine (1000 mg/m2) I.V. for 30 min, for a total of six doses on days 1, 8, 15, 29, 36 and 43.

Investigational medicinal product name	FOLFIRI.3
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Solution for injection
Routes of administration	Intravenous use

Dosage and administration details:

After 2 months of nab-paclitaxel + Gemcitabine, FOLFIRI.3 sequence :
irinotecan 90 mg/m2 I.V. for 60 min on D1, together with folinic acid 400 mg/m2 given as a 2-h I.V. infusion,
immediately followed by continuous fluorouracil (5-FU) infusion at a dose of 2000 mg/m2 over a 46-h period, and irinotecan, 90 mg/m2 I.V. for 60 min repeated on D3 at the end of the 5-FU infusion.

The chemotherapy cycles were repeated every 14 days for 2 months. This sequence (gemcitabine + nab-paclitaxel followed by FOLFIRI.3) was repeated until disease progression or limiting toxicity.

Arm title	arm B : GN

Arm description:

gemcitabine + nab-paclitaxel (standard first-line therapy)

Arm type	Active comparator
Investigational medicinal product name	Nab-paclitaxel
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Solution for injection
Routes of administration	Intravenous use

Dosage and administration details:

Nab-paclitaxel = 125 mg/m2 I.V. for 30 min.
Gemcitabine + nab-paclitaxel were given until disease progression, unacceptable toxicity or patient refusal.

Investigational medicinal product name	Gemcitabine
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Powder for concentrate and solution for solution for infusion
Routes of administration	Intravenous use

Dosage and administration details:

Gemcitabine = 1000 mg/m2 I.V. for 30 min.
gemcitabine + nab-paclitaxel were given until disease progression, unacceptable toxicity or patient refusal.

Number of subjects in period 1	arm A : GN + FOLFIRI.3	arm B : GN
Started	64	63
Completed	62	60
Not completed	2	3
Patient not treated	1	1
Death	1	2

Baseline characteristics

Reporting groups	
Reporting group title	arm A : GN + FOLFIRI.3
Reporting group description: gemcitabine + nab-paclitaxel + FOLFIRI.3 =FIRGEMAX arm	
Reporting group title	arm B : GN
Reporting group description: gemcitabine + nab-paclitaxel (standard first-line therapy)	

Reporting group values	arm A : GN + FOLFIRI.3	arm B : GN	Total
Number of subjects	64	63	127
Age categorical Units: Subjects			
In utero	0	0	0
Preterm newborn infants (gestational age < 37 wks)	0	0	0
Newborns (0-27 days)	0	0	0
Infants and toddlers (28 days-23 months)	0	0	0
Children (2-11 years)	0	0	0
Adolescents (12-17 years)	0	0	0
Adults (18-64 years)	30	30	60
From 65-84 years	34	33	67
85 years and over	0	0	0
Age continuous Units: years			
arithmetic mean	63.5	64.1	
full range (min-max)	38.3 to 76.0	41.0 to 76.0	-
Gender categorical Units: Subjects			
Female	28	34	62
Male	36	29	65
ECOG PS Units: Subjects			
PS 0	24	23	47
PS 1	33	32	65
PS 2	7	8	15
Nb of metastatic sites Units: Subjects			
One	29	37	66
> 1	35	26	61
Previous surgery Units: Subjects			
Yes	8	3	11
No	56	60	116
Previous radiotherapy Units: Subjects			
Yes	0	2	2

No	64	61	125
Previous chemotheray Units: Subjects			
Yes	7	3	10
No	57	60	117
CA 19.9 Units: UI/mL			
median	1346	5575	
full range (min-max)	0.8 to 131600	0.6 to 534806	-

Subject analysis sets

Subject analysis set title	mITT (arm A : GN + FOLFIRI.3)
Subject analysis set type	Modified intention-to-treat

Subject analysis set description:

Randomised patients receiving at least one dose of treatment in arm A

Subject analysis set title	mITT (arm B : GN)
Subject analysis set type	Modified intention-to-treat

Subject analysis set description:

Randomised patients receiving at least one dose of treatment in arm B

Reporting group values	mITT (arm A : GN + FOLFIRI.3)	mITT (arm B : GN)	
Number of subjects	62	60	
Age categorical Units: Subjects			
In utero	0	0	
Preterm newborn infants (gestational age < 37 wks)	0	0	
Newborns (0-27 days)	0	0	
Infants and toddlers (28 days-23 months)	0	0	
Children (2-11 years)	0	0	
Adolescents (12-17 years)	0	0	
Adults (18-64 years)	29	29	
From 65-84 years	33	31	
85 years and over	0	0	
Age continuous Units: years			
arithmetic mean	63.3	64.1	
full range (min-max)	38.3 to 76.0	41.0 to 76.0	
Gender categorical Units: Subjects			
Female	28	32	
Male	34	28	
ECOG PS Units: Subjects			
PS 0	24	22	
PS 1	31	31	
PS 2	7	7	
Nb of metastatic sites Units: Subjects			

One	28	35	
> 1	34	25	
Previous surgery Units: Subjects			
Yes	8	3	
No	54	57	
Previous radiotherapy Units: Subjects			
Yes	0	2	
No	62	58	
Previous chemotheray Units: Subjects			
Yes	7	3	
No	55	57	
CA 19.9 Units: UI/mL			
median	1067	4358.5	
full range (min-max)	0.8 to 131600	0.6 to 534806	

End points

End points reporting groups

Reporting group title	arm A : GN + FOLFIRI.3
Reporting group description: gemcitabine + nab-paclitaxel + FOLFIRI.3 =FIRGEMAX arm	
Reporting group title	arm B : GN
Reporting group description: gemcitabine + nab-paclitaxel (standard first-line therapy)	
Subject analysis set title	mITT (arm A : GN + FOLFIRI.3)
Subject analysis set type	Modified intention-to-treat
Subject analysis set description: Randomised patients receiving at least one dose of treatment in arm A	
Subject analysis set title	mITT (arm B : GN)
Subject analysis set type	Modified intention-to-treat
Subject analysis set description: Randomised patients receiving at least one dose of treatment in arm B	

Primary: PFS rate at 6 months

End point title	PFS rate at 6 months[1]

End point description:

The primary end point was 6-month PFS rate based on TDM.
In the 62 mITT patients in arm A: If 32 or more patients are alive without progression at 6 months, we conclude that the treatment is effective.

End point type	Primary
End point timeframe: at 6 months post randomization	

Notes:

[1] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.
Justification: This is a non-comparative study, so there are no inferential statistics.

End point values	mITT (arm A : GN + FOLFIRI.3)	mITT (arm B : GN)		
Subject group type	Subject analysis set	Subject analysis set		
Number of subjects analysed	62	60		
Units: patients				
Yes	28	14		
No	34	46		

Statistical analyses

No statistical analyses for this end point

Secondary: Progression-free survival

End point title	Progression-free survival

End point description:

Progression free-survival was measured from the date of randomization to the date of first progression (radiological or clinical) or the date of death from any cause. Alive patients free of progression were censored at the date of the last follow-up visit.

End point type	Secondary

End point timeframe:

until the last follow-up or the apperance of progression or death

End point values	mITT (arm A : GN + FOLFIRI.3)	mITT (arm B : GN)		
Subject group type	Subject analysis set	Subject analysis set		
Number of subjects analysed	62	60		
Units: months				
median (confidence interval 95%)	6.1 (3.7 to 7.6)	4.2 (2.4 to 6.0)		

Attachments (see zip file)	PFS_mITT/Figure 1A.png

Statistical analyses

No statistical analyses for this end point

Secondary: Overall survival

End point title	Overall survival

End point description:

Overall survival was defined as the time between randomization and death (all causes). Patients alive were censored at the last follow-up.

End point type	Secondary

End point timeframe:

until the end of the follow-up or death (Whatever the cause)

End point values	mITT (arm A : GN + FOLFIRI.3)	mITT (arm B : GN)		
Subject group type	Subject analysis set	Subject analysis set		
Number of subjects analysed	62	60		
Units: months				
median (confidence interval 95%)	11.8 (8.8 to 15.0)	11.2 (8.2 to 13.2)		

Attachments (see zip file)	OS_mITT/Figure 1B.png

Statistical analyses

No statistical analyses for this end point

Secondary: Objective response rate

End point title	Objective response rate

End point description:

End point type	Secondary

End point timeframe:

All tumour assessments carried out between study start and D1 of the last treatment (+1.5 months) received by every patient

End point values	mITT (arm A : GN + FOLFIRI.3)	mITT (arm B : GN)		
Subject group type	Subject analysis set	Subject analysis set		
Number of subjects analysed	62	60		
Units: %				
number (confidence interval 95%)	40.3 (28.1 to 53.6)	26.7 (16.1 to 39.7)		

Statistical analyses

No statistical analyses for this end point

Adverse events

Adverse events information

Timeframe for reporting adverse events:

All adverse events (related and unrelated, expected and unexpected) were collected after each cycles of treatment until the end of the treatment period.

Adverse event reporting additional description:

Adverse events were analyzed on the population of patients who received at least one dose of treatment and regarding the treatment really received by the patient (Two
patients randomized in the GN arm received GN + FOLFIRI.3 and so were analyzed in GN + FOLFIRI.3 for tolerance)

Assessment type	Systematic

Dictionary used

Dictionary name	NCI-CTC
Dictionary version	4.0

Reporting groups

Reporting group title	arm A : GN + FOLFIRI.3
Reporting group description: -	
Reporting group title	arm B :GN

Reporting group description: -

Serious adverse events	arm A : GN + FOLFIRI.3	arm B :GN	
Total subjects affected by serious adverse events			
subjects affected / exposed	36 / 64 (56.25%)	24 / 58 (41.38%)	
number of deaths (all causes)	53	54	
number of deaths resulting from adverse events	4	5	
Vascular disorders			
Deep vein thrombosis			
subjects affected / exposed	0 / 64 (0.00%)	1 / 58 (1.72%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
General disorders and administration site conditions			
Asthenia			
subjects affected / exposed	2 / 64 (3.13%)	2 / 58 (3.45%)	
occurrences causally related to treatment / all	0 / 2	2 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
General physical health deterioration			
subjects affected / exposed	9 / 64 (14.06%)	5 / 58 (8.62%)	
occurrences causally related to treatment / all	3 / 9	4 / 5	
deaths causally related to treatment / all	0 / 0	0 / 0	

Hyperthermia			
subjects affected / exposed	3 / 64 (4.69%)	0 / 58 (0.00%)	
occurrences causally related to treatment / all	1 / 3	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Pyrexia			
subjects affected / exposed	0 / 64 (0.00%)	1 / 58 (1.72%)	
occurrences causally related to treatment / all	0 / 0	1 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Generalised oedema			
subjects affected / exposed	1 / 64 (1.56%)	0 / 58 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Respiratory, thoracic and mediastinal disorders			
Bronchopneumopathy			
subjects affected / exposed	0 / 64 (0.00%)	1 / 58 (1.72%)	
occurrences causally related to treatment / all	0 / 0	1 / 1	
deaths causally related to treatment / all	0 / 0	1 / 1	
Lung disorder			
subjects affected / exposed	0 / 64 (0.00%)	1 / 58 (1.72%)	
occurrences causally related to treatment / all	0 / 0	1 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Pulmonary embolism			
subjects affected / exposed	2 / 64 (3.13%)	2 / 58 (3.45%)	
occurrences causally related to treatment / all	2 / 2	1 / 2	
deaths causally related to treatment / all	2 / 2	0 / 0	
Respiratory disorder			
subjects affected / exposed	0 / 64 (0.00%)	1 / 58 (1.72%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Respiratory distress			
subjects affected / exposed	1 / 64 (1.56%)	0 / 58 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	

Psychiatric disorders			
Confusional state			
subjects affected / exposed	1 / 64 (1.56%)	0 / 58 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Product issues			
Device occlusion			
subjects affected / exposed	1 / 64 (1.56%)	1 / 58 (1.72%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Investigations			
Angiocardiogram			
subjects affected / exposed	1 / 64 (1.56%)	0 / 58 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Injury, poisoning and procedural complications			
Accidental overdose			
subjects affected / exposed	1 / 64 (1.56%)	0 / 58 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Fall			
subjects affected / exposed	1 / 64 (1.56%)	0 / 58 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Congenital, familial and genetic disorders			
Hypertrophic cardiomyopathy			
subjects affected / exposed	0 / 64 (0.00%)	1 / 58 (1.72%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Cardiac disorders			
Arrhythmia			
subjects affected / exposed	0 / 64 (0.00%)	1 / 58 (1.72%)	
occurrences causally related to treatment / all	0 / 0	1 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Atrioventricular block complete			

subjects affected / exposed	1 / 64 (1.56%)	0 / 58 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Cardiac arrest			
subjects affected / exposed	0 / 64 (0.00%)	2 / 58 (3.45%)	
occurrences causally related to treatment / all	0 / 0	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 2	
Cardiac failure			
subjects affected / exposed	0 / 64 (0.00%)	2 / 58 (3.45%)	
occurrences causally related to treatment / all	0 / 0	0 / 2	
deaths causally related to treatment / all	0 / 0	1 / 1	
Myocardial infarction			
subjects affected / exposed	1 / 64 (1.56%)	0 / 58 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Nervous system disorders			
Cerebrovascular accident			
subjects affected / exposed	0 / 64 (0.00%)	1 / 58 (1.72%)	
occurrences causally related to treatment / all	0 / 0	1 / 1	
deaths causally related to treatment / all	0 / 0	1 / 1	
Transient ischaemic attack			
subjects affected / exposed	1 / 64 (1.56%)	0 / 58 (0.00%)	
occurrences causally related to treatment / all	1 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Blood and lymphatic system disorders			
Anaemia			
subjects affected / exposed	1 / 64 (1.56%)	1 / 58 (1.72%)	
occurrences causally related to treatment / all	1 / 1	1 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Bone marrow failure			
subjects affected / exposed	0 / 64 (0.00%)	1 / 58 (1.72%)	
occurrences causally related to treatment / all	0 / 0	1 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Febrile bone marrow aplasia			

subjects affected / exposed	1 / 64 (1.56%)	2 / 58 (3.45%)	
occurrences causally related to treatment / all	1 / 1	2 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Thrombocytopenia			
subjects affected / exposed	2 / 64 (3.13%)	0 / 58 (0.00%)	
occurrences causally related to treatment / all	2 / 2	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Gastrointestinal disorders			
Colitis			
subjects affected / exposed	1 / 64 (1.56%)	0 / 58 (0.00%)	
occurrences causally related to treatment / all	1 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Diarrhoea			
subjects affected / exposed	2 / 64 (3.13%)	1 / 58 (1.72%)	
occurrences causally related to treatment / all	2 / 2	1 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Enteritis			
subjects affected / exposed	1 / 64 (1.56%)	0 / 58 (0.00%)	
occurrences causally related to treatment / all	1 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Intestinal obstruction			
subjects affected / exposed	2 / 64 (3.13%)	0 / 58 (0.00%)	
occurrences causally related to treatment / all	1 / 2	0 / 0	
deaths causally related to treatment / all	0 / 1	0 / 0	
Subileus			
subjects affected / exposed	2 / 64 (3.13%)	0 / 58 (0.00%)	
occurrences causally related to treatment / all	1 / 2	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Vomiting			
subjects affected / exposed	3 / 64 (4.69%)	1 / 58 (1.72%)	
occurrences causally related to treatment / all	2 / 3	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Abdominal pain			

subjects affected / exposed	4 / 64 (6.25%)	1 / 58 (1.72%)	
occurrences causally related to treatment / all	0 / 4	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Abdominal pain upper			
subjects affected / exposed	0 / 64 (0.00%)	1 / 58 (1.72%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Ascites			
subjects affected / exposed	0 / 64 (0.00%)	1 / 58 (1.72%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Duodenal obstruction			
subjects affected / exposed	1 / 64 (1.56%)	0 / 58 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Hepatobiliary disorders			
Cholangitis			
subjects affected / exposed	2 / 64 (3.13%)	0 / 58 (0.00%)	
occurrences causally related to treatment / all	1 / 2	0 / 0	
deaths causally related to treatment / all	0 / 1	0 / 0	
Biliary tract disorder			
subjects affected / exposed	0 / 64 (0.00%)	1 / 58 (1.72%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Cholecystitis			
subjects affected / exposed	1 / 64 (1.56%)	0 / 58 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Jaundice			
subjects affected / exposed	2 / 64 (3.13%)	0 / 58 (0.00%)	
occurrences causally related to treatment / all	0 / 2	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Skin and subcutaneous tissue disorders			

Dermatitis bullous			
subjects affected / exposed	0 / 64 (0.00%)	1 / 58 (1.72%)	
occurrences causally related to treatment / all	0 / 0	1 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Skin toxicity			
subjects affected / exposed	0 / 64 (0.00%)	1 / 58 (1.72%)	
occurrences causally related to treatment / all	0 / 0	1 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Renal and urinary disorders			
Acute kidney injury			
subjects affected / exposed	0 / 64 (0.00%)	2 / 58 (3.45%)	
occurrences causally related to treatment / all	0 / 0	2 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Musculoskeletal and connective tissue disorders			
Back pain			
subjects affected / exposed	2 / 64 (3.13%)	0 / 58 (0.00%)	
occurrences causally related to treatment / all	0 / 2	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Infections and infestations			
Campylobacter colitis			
subjects affected / exposed	1 / 64 (1.56%)	0 / 58 (0.00%)	
occurrences causally related to treatment / all	1 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Catheter site infection			
subjects affected / exposed	2 / 64 (3.13%)	0 / 58 (0.00%)	
occurrences causally related to treatment / all	1 / 2	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Device related infection			
subjects affected / exposed	2 / 64 (3.13%)	2 / 58 (3.45%)	
occurrences causally related to treatment / all	2 / 2	2 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Enterobacter sepsis			

subjects affected / exposed	0 / 64 (0.00%)	1 / 58 (1.72%)	
occurrences causally related to treatment / all	0 / 0	1 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Erysipelas			
subjects affected / exposed	1 / 64 (1.56%)	1 / 58 (1.72%)	
occurrences causally related to treatment / all	0 / 1	1 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Infection			
subjects affected / exposed	0 / 64 (0.00%)	1 / 58 (1.72%)	
occurrences causally related to treatment / all	0 / 0	1 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Liver abscess			
subjects affected / exposed	0 / 64 (0.00%)	1 / 58 (1.72%)	
occurrences causally related to treatment / all	0 / 0	1 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Pneumonia			
subjects affected / exposed	0 / 64 (0.00%)	1 / 58 (1.72%)	
occurrences causally related to treatment / all	0 / 0	1 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Sepsis			
subjects affected / exposed	2 / 64 (3.13%)	2 / 58 (3.45%)	
occurrences causally related to treatment / all	2 / 2	1 / 2	
deaths causally related to treatment / all	0 / 0	0 / 1	
Septic shock			
subjects affected / exposed	1 / 64 (1.56%)	1 / 58 (1.72%)	
occurrences causally related to treatment / all	1 / 1	1 / 1	
deaths causally related to treatment / all	1 / 1	1 / 1	
Staphylococcal sepsis			
subjects affected / exposed	0 / 64 (0.00%)	2 / 58 (3.45%)	
occurrences causally related to treatment / all	0 / 0	1 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Biliary sepsis			

subjects affected / exposed	0 / 64 (0.00%)	1 / 58 (1.72%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Bronchitis			
subjects affected / exposed	0 / 64 (0.00%)	1 / 58 (1.72%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Nasopharyngitis			
subjects affected / exposed	1 / 64 (1.56%)	0 / 58 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Peritonitis			
subjects affected / exposed	1 / 64 (1.56%)	0 / 58 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Metabolism and nutrition disorders			
Decreased appetite			
subjects affected / exposed	1 / 64 (1.56%)	0 / 58 (0.00%)	
occurrences causally related to treatment / all	1 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Dehydration			
subjects affected / exposed	1 / 64 (1.56%)	0 / 58 (0.00%)	
occurrences causally related to treatment / all	1 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Hypokalaemia			
subjects affected / exposed	4 / 64 (6.25%)	0 / 58 (0.00%)	
occurrences causally related to treatment / all	3 / 4	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Malnutrition			
subjects affected / exposed	1 / 64 (1.56%)	0 / 58 (0.00%)	
occurrences causally related to treatment / all	1 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Diabetic ketoacidosis			

subjects affected / exposed	1 / 64 (1.56%)	1 / 58 (1.72%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Hypercalcaemia			
subjects affected / exposed	1 / 64 (1.56%)	0 / 58 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	

Frequency threshold for reporting non-serious adverse events: 5 %

Non-serious adverse events	arm A : GN + FOLFIRI.3	arm B :GN	
Total subjects affected by non-serious adverse events			
subjects affected / exposed	63 / 64 (98.44%)	58 / 58 (100.00%)	
Vascular disorders			
Venous thromboembolic event			
subjects affected / exposed	10 / 64 (15.63%)	6 / 58 (10.34%)	
occurrences (all)	10	6	
Hypertension			
subjects affected / exposed	1 / 64 (1.56%)	3 / 58 (5.17%)	
occurrences (all)	1	3	
General disorders and administration site conditions			
Dyspepsia			
subjects affected / exposed	2 / 64 (3.13%)	3 / 58 (5.17%)	
occurrences (all)	2	3	
Fatigue			
subjects affected / exposed	52 / 64 (81.25%)	45 / 58 (77.59%)	
occurrences (all)	52	45	
Fever			
subjects affected / exposed	24 / 64 (37.50%)	18 / 58 (31.03%)	
occurrences (all)	24	18	
Oedema of the limbs			
subjects affected / exposed	16 / 64 (25.00%)	14 / 58 (24.14%)	
occurrences (all)	16	14	
Immune system disorders			

Allergic reaction			
subjects affected / exposed	6 / 64 (9.38%)	4 / 58 (6.90%)	
occurrences (all)	6	4	
Respiratory, thoracic and mediastinal disorders			
Dyspnoea			
subjects affected / exposed	2 / 64 (3.13%)	3 / 58 (5.17%)	
occurrences (all)	2	3	
Epistaxis			
subjects affected / exposed	6 / 64 (9.38%)	3 / 58 (5.17%)	
occurrences (all)	6	3	
Cough			
subjects affected / exposed	2 / 64 (3.13%)	7 / 58 (12.07%)	
occurrences (all)	2	7	
Psychiatric disorders			
Anxiety			
subjects affected / exposed	2 / 64 (3.13%)	3 / 58 (5.17%)	
occurrences (all)	2	3	
Depression			
subjects affected / exposed	2 / 64 (3.13%)	3 / 58 (5.17%)	
occurrences (all)	2	3	
Insomnia			
subjects affected / exposed	3 / 64 (4.69%)	4 / 58 (6.90%)	
occurrences (all)	3	4	
Investigations			
Alanine aminotransferase increased			
subjects affected / exposed	54 / 64 (84.38%)	42 / 58 (72.41%)	
occurrences (all)	54	42	
Aspartate aminotransferase increased			
subjects affected / exposed	52 / 64 (81.25%)	39 / 58 (67.24%)	
occurrences (all)	52	39	
Bilirubin increased			
subjects affected / exposed	19 / 64 (29.69%)	14 / 58 (24.14%)	
occurrences (all)	19	14	
Creatinine increased			
subjects affected / exposed	5 / 64 (7.81%)	2 / 58 (3.45%)	
occurrences (all)	5	2	

Gamma-glutamyltransferase increased			
subjects affected / exposed	22 / 64 (34.38%)	15 / 58 (25.86%)	
occurrences (all)	22	15	
Hemoglobin increased			
subjects affected / exposed	3 / 64 (4.69%)	5 / 58 (8.62%)	
occurrences (all)	3	5	
Neutrophil count decreased			
subjects affected / exposed	45 / 64 (70.31%)	36 / 58 (62.07%)	
occurrences (all)	45	36	
Lymphocyte count decreased			
subjects affected / exposed	19 / 64 (29.69%)	5 / 58 (8.62%)	
occurrences (all)	19	5	
Polynuclear neutrophils increased			
subjects affected / exposed	54 / 64 (84.38%)	47 / 58 (81.03%)	
occurrences (all)	54	47	
Weight loss			
subjects affected / exposed	9 / 64 (14.06%)	9 / 58 (15.52%)	
occurrences (all)	9	9	
Platelet count decreased			
subjects affected / exposed	43 / 64 (67.19%)	38 / 58 (65.52%)	
occurrences (all)	43	38	
Hypoalbuminaemia			
subjects affected / exposed	15 / 64 (23.44%)	8 / 58 (13.79%)	
occurrences (all)	15	8	
Nervous system disorders			
Headache			
subjects affected / exposed	4 / 64 (6.25%)	7 / 58 (12.07%)	
occurrences (all)	4	7	
Dysgeusia			
subjects affected / exposed	5 / 64 (7.81%)	5 / 58 (8.62%)	
occurrences (all)	5	5	
Paresthesia			
subjects affected / exposed	22 / 64 (34.38%)	23 / 58 (39.66%)	
occurrences (all)	22	23	
Neuropathy peripheral			

subjects affected / exposed occurrences (all)	15 / 64 (23.44%) 15	16 / 58 (27.59%) 16	
Blood and lymphatic system disorders Anemia subjects affected / exposed occurrences (all)	 58 / 64 (90.63%) 58	 55 / 58 (94.83%) 55	
Ear and labyrinth disorders Vertigo subjects affected / exposed occurrences (all)	 5 / 64 (7.81%) 5	 1 / 58 (1.72%) 1	
Gastrointestinal disorders Constipation subjects affected / exposed occurrences (all) Diarrhoea subjects affected / exposed occurrences (all) Stomach pain subjects affected / exposed occurrences (all) Abdominal pain subjects affected / exposed occurrences (all) Mucitis subjects affected / exposed occurrences (all) Nausea subjects affected / exposed occurrences (all) Vomiting subjects affected / exposed occurrences (all) Oral mucositis subjects affected / exposed occurrences (all)	 15 / 64 (23.44%) 15 45 / 64 (70.31%) 45 6 / 64 (9.38%) 6 24 / 64 (37.50%) 24 14 / 64 (21.88%) 14 42 / 64 (65.63%) 42 30 / 64 (46.88%) 30 2 / 64 (3.13%) 2	 18 / 58 (31.03%) 18 35 / 58 (60.34%) 35 2 / 58 (3.45%) 2 15 / 58 (25.86%) 15 12 / 58 (20.69%) 12 30 / 58 (51.72%) 30 21 / 58 (36.21%) 21 3 / 58 (5.17%) 3	
Skin and subcutaneous tissue disorders			

Alopecia			
subjects affected / exposed	31 / 64 (48.44%)	32 / 58 (55.17%)	
occurrences (all)	31	32	
Hyperhidrosis			
subjects affected / exposed	0 / 64 (0.00%)	3 / 58 (5.17%)	
occurrences (all)	0	3	
Skin dryness			
subjects affected / exposed	4 / 64 (6.25%)	3 / 58 (5.17%)	
occurrences (all)	4	3	
Palmar-plantar erythrodysaesthesia syndrome			
subjects affected / exposed	8 / 64 (12.50%)	3 / 58 (5.17%)	
occurrences (all)	8	3	
Musculoskeletal and connective tissue disorders			
Back pain			
subjects affected / exposed	5 / 64 (7.81%)	3 / 58 (5.17%)	
occurrences (all)	5	3	
Myalgia			
subjects affected / exposed	6 / 64 (9.38%)	6 / 58 (10.34%)	
occurrences (all)	6	6	
Infections and infestations			
Bronchial infection			
subjects affected / exposed	1 / 64 (1.56%)	9 / 58 (15.52%)	
occurrences (all)	1	9	
Metabolism and nutrition disorders			
Anorexia			
subjects affected / exposed	38 / 64 (59.38%)	26 / 58 (44.83%)	
occurrences (all)	38	26	
Hyperglycaemia			
subjects affected / exposed	4 / 64 (6.25%)	3 / 58 (5.17%)	
occurrences (all)	4	3	
Hyperkalaemia			
subjects affected / exposed	14 / 64 (21.88%)	4 / 58 (6.90%)	
occurrences (all)	14	4	
Hypocalcaemia			
subjects affected / exposed	9 / 64 (14.06%)	4 / 58 (6.90%)	
occurrences (all)	9	4	

Hypokalaemia subjects affected / exposed occurrences (all)	9 / 64 (14.06%) 9	4 / 58 (6.90%) 4	
Hyponatraemia subjects affected / exposed occurrences (all)	15 / 64 (23.44%) 15	8 / 58 (13.79%) 8	

More information

Substantial protocol amendments (globally)

Were there any global substantial amendments to the protocol? No

Interruptions (globally)

Were there any global interruptions to the trial? No

Limitations and caveats

None reported

Online references

http://www.ncbi.nlm.nih.gov/pubmed/32623182